Does the media refer more to BCRX or KRYS?

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 7 articles in the media. Krystal Biotech's average media sentiment score of 1.30 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYMR or BCRX?

In the previous week, Kymera Therapeutics had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 9 mentions for Kymera Therapeutics and 7 mentions for BioCryst Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 1.24 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCRX or IONS?

In the previous week, Ionis Pharmaceuticals had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYTK or BCRX?

In the previous week, Cytokinetics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat Cytokinetics' score of 0.65 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioCryst Pharmaceuticals (BCRX) Competitors

$9.56 -0.10 (-1.04%)

As of 08/21/2026 04:00 PM Eastern

Compare

BCRX vs. KRYS, NUVL, KYMR, IONS, and CYTK

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? BioCryst Pharmaceuticals's main competitors and comparable companies include Krystal Biotech (KRYS), Nuvalent (NUVL), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Cytokinetics (CYTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Krystal Biotech?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Krystal Biotech has a net margin of 54.82% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Krystal Biotech's return on equity of 19.34% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Krystal Biotech	54.82%	19.34%	17.65%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Krystal Biotech. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

BioCryst Pharmaceuticals presently has a consensus price target of $20.60, suggesting a potential upside of 115.48%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 5.43%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 7 articles in the media. Krystal Biotech's average media sentiment score of 1.30 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats BioCryst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Nuvalent?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Nuvalent. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 0 mentions for Nuvalent. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat Nuvalent's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Positive
Nuvalent	Neutral

Nuvalent has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Nuvalent's return on equity of -40.11% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Nuvalent	N/A	-40.11%	-35.43%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

BioCryst Pharmaceuticals presently has a consensus price target of $20.60, suggesting a potential upside of 115.48%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

BioCryst Pharmaceuticals beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

In the previous week, Kymera Therapeutics had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 9 mentions for Kymera Therapeutics and 7 mentions for BioCryst Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 1.24 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics currently has a consensus price target of $125.65, indicating a potential upside of 4.88%. BioCryst Pharmaceuticals has a consensus price target of $20.60, indicating a potential upside of 115.48%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	254.05	-$311.35M	-$3.24	N/A
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Summary

Kymera Therapeutics and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Ionis Pharmaceuticals' net margin of -64.76%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

BioCryst Pharmaceuticals presently has a consensus price target of $20.60, suggesting a potential upside of 115.48%. Ionis Pharmaceuticals has a consensus price target of $94.15, suggesting a potential upside of 57.60%. Given BioCryst Pharmaceuticals' higher probable upside, equities research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Ionis Pharmaceuticals had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat BioCryst Pharmaceuticals' score of 0.95 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A
Ionis Pharmaceuticals	$944M	10.52	-$381.39M	-$3.46	N/A

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioCryst Pharmaceuticals beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A

Cytokinetics presently has a consensus target price of $102.20, indicating a potential upside of 33.00%. BioCryst Pharmaceuticals has a consensus target price of $20.60, indicating a potential upside of 115.48%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cytokinetics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat Cytokinetics' score of 0.65 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Summary

BioCryst Pharmaceuticals beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.44B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-6.37	11.62	272.60	24.24
Price / Sales	2.60	1,338.17	618.96	99.81
Price / Cash	7.71	105.14	78.62	53.99
Price / Book	-5.37	16.80	13.05	6.20
Net Income	$263.86M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-1.85%	3.29%	2.09%	0.08%
1 Month Performance	1.92%	8.23%	6.64%	3.88%
1 Year Performance	11.68%	55.05%	25.02%	16.98%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	2.8354 of 5 stars	$9.56 -1.0%	$20.60 +115.5%	+11.7%	$2.44B	$940.61M	N/A	530
KRYS Krystal Biotech	4.1259 of 5 stars	$335.73 +1.0%	$365.40 +8.8%	+130.3%	$9.83B	$440.48M	42.07	210	Positive News Analyst Downgrade
NUVL Nuvalent	2.1252 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
KYMR Kymera Therapeutics	1.5005 of 5 stars	$121.41 +3.4%	$125.65 +3.5%	+171.7%	$9.76B	$39.21M	N/A	170	News Coverage Positive News
IONS Ionis Pharmaceuticals	3.5653 of 5 stars	$58.63 +2.4%	$94.65 +61.4%	+39.9%	$9.51B	$944M	N/A	1,402	News Coverage Positive News Analyst Upgrade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. KRYS, NUVL, KYMR, IONS, and CYTK

How does BioCryst Pharmaceuticals compare to Krystal Biotech?

Summary

How does BioCryst Pharmaceuticals compare to Nuvalent?

Summary

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. KRYS, NUVL, KYMR, IONS, and CYTK

How does BioCryst Pharmaceuticals compare to Krystal Biotech?

Is BCRX or KRYS more profitable?

Do insiders & institutionals have more ownership in BCRX or KRYS?

Which has higher earnings & valuation, BCRX or KRYS?

Which has more risk & volatility, BCRX or KRYS?

Do analysts recommend BCRX or KRYS?

Does the media refer more to BCRX or KRYS?

Summary

How does BioCryst Pharmaceuticals compare to Nuvalent?

Does the media favor BCRX or NUVL?

Is BCRX or NUVL more profitable?

Do institutionals and insiders hold more shares of BCRX or NUVL?

Which has stronger valuation and earnings, BCRX or NUVL?

Which has more volatility & risk, BCRX or NUVL?

Do analysts recommend BCRX or NUVL?

Summary

How does BioCryst Pharmaceuticals compare to Kymera Therapeutics?

Which has more volatility & risk, KYMR or BCRX?

Does the media prefer KYMR or BCRX?

Do analysts rate KYMR or BCRX?

Do institutionals & insiders hold more shares of KYMR or BCRX?

Which has better earnings and valuation, KYMR or BCRX?

Is KYMR or BCRX more profitable?

Summary

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Is BCRX or IONS more profitable?

Do analysts prefer BCRX or IONS?

Does the media favor BCRX or IONS?

Which has preferable valuation and earnings, BCRX or IONS?

Which has more volatility and risk, BCRX or IONS?

Do institutionals & insiders have more ownership in BCRX or IONS?

Summary

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Which has better earnings and valuation, CYTK or BCRX?

Do analysts prefer CYTK or BCRX?

Does the media prefer CYTK or BCRX?

Which has more risk & volatility, CYTK or BCRX?

Do institutionals and insiders believe in CYTK or BCRX?

Is CYTK or BCRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools